CVT-E002

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2015
01220012015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
BACKGROUND Chronic lymphocytic leukemia (CLL) patients are at high risk for acute respiratory illness (ARI). OBJECTIVE We… (More)
Is this relevant?
2012
2012
Cells belonging to the innate immune system are referred to as natural killer (NK) cells. We recently demonstrated that normal… (More)
Is this relevant?
2011
2011
CVT-E002 (a proprietary extract) was found to be effective in the prevention of upper respiratory infections (URIs) in healthy… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2009
2009
The present study evaluated the dose-related effects of CVT-E002, a proprietary extract of Panax quinquefolius (CV Technologies… (More)
Is this relevant?
2008
2008
CVT-E002 (sold commercially as COLD-fX) is a patented, polysaccharide-rich extract of North American ginseng (Panax quinquefolium… (More)
Is this relevant?
2006
2006
BACKGROUND COLD-fX (CVT-E002), a proprietary extract of the roots of North American ginseng (Panax quinquefolium), rich in poly… (More)
Is this relevant?
2004
2004
OBJECTIVES To compare a proprietary extract of American ginseng, CVT-E002, with placebo in preventing acute respiratory illness… (More)
Is this relevant?
2004
2004
A patented aqueous extract from North American ginseng (Panax quinquefolium), containing mainly oligosaccharides and… (More)
Is this relevant?
2003
2003
CVT-E002, a proprietary extract from North American ginseng (Panax quinquefolium) showed immunomodulating activity. Cytochrome… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2001
2001
The activity of CVT-E002, an aqueous extract containing mainly oligosaccharides and polysaccharides from North American ginseng… (More)
Is this relevant?